Richard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both immune oncology and inflammatory diseases. In healthy tissues ...

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, ...

Inhibiting GLS1 reduced high blood pressure in the right side of the heart of PAH rats and improved various measures of heart ...

Biomedical scientists at the University of California, Riverside have received a $3.7 million grant from the National Institutes of Health to study the role of sex-specific immune responses in obesity ...

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...

Atherosclerosis risk is elevated in diabetic patients, but the underlying mechanism such as the involvement of macrophages remains unclear. Here, we investigated the underlying mechanism related to ...

Researchers from Sun Yat-sen University and affiliated organizations published data from a study that aimed to assess the role of the TNF receptor-associated factor 6 (TRAF6), E3 ubiquitin ligase ...

Inflammatory processes are the body’s defence against local damage and disease. Inflammation involves the influx into organs of immune cells (white blood cells) from the blood. These cells deal with ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will ...